The VMVN Study: Virological Monitoring in Viet Nam
NCT01317498 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 650
Last updated 2018-08-03
Summary
The purpose of the study is to test the hypothesis that the addition of routine viral load testing to the standard laboratory monitoring of HIV patients on first-line antiretroviral treatment (ART) in Vietnam will result in better clinical outcomes for patients.
Conditions
- HIV Infection
- AIDS
Interventions
- OTHER
-
Standard Care
CD4, liver function and CBC every 6 months
- OTHER
-
Virological Monitoring
Viral Load test every 6 months
Sponsors & Collaborators
-
Bach Mai Hospital
collaborator OTHER -
Roche Molecular Systems, Inc
collaborator INDUSTRY -
Beth Israel Deaconess Medical Center
lead OTHER
Principal Investigators
-
Todd M Pollack, MD · Beth Israel Deaconess Medical Center
-
Pham T Thuy, MD, PhD · Bach Mai Hospital, Hanoi, Vietnam
-
Julian Elliott, MBBS, PhD · Alfred Hospital, Melbourne, Australia
-
Donn J Colby, MD, MPH · Center for Applied Research on Men and Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-30
- Primary Completion
- 2018-06-30
- Completion
- 2018-06-30
Countries
- Vietnam
Study Locations
More Related Trials
-
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00435929 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046 ·Status: COMPLETED ·Phase: NA
-
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients
NCT00071097 ·Status: COMPLETED ·Phase: PHASE2
-
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
NCT01702090 ·Status: COMPLETED ·Phase: PHASE4
-
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
NCT00110877 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
NCT00025727 ·Status: UNKNOWN ·Phase: PHASE3
-
Pharmacokinetics of Low Dose Ritonavir
NCT00622206 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
NCT00144833 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
NCT00458302 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients
NCT04592315 ·Status: COMPLETED ·Phase: PHASE1
-
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
NCT00027339 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
NCT00358917 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
NCT00002020 ·Status: COMPLETED ·Phase: NA
-
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
NCT00144170 ·Status: COMPLETED ·Phase: PHASE3
-
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT00450580 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
NCT00357552 ·Status: COMPLETED ·Phase: NA
-
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
NCT00054717 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients
NCT00647244 ·Status: COMPLETED ·Phase: PHASE4
-
Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)
NCT00312169 ·Status: COMPLETED
-
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
NCT00046033 ·Status: COMPLETED ·Phase: PHASE2
-
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
NCT00530920 ·Status: COMPLETED ·Phase: PHASE2
-
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure
NCT00002047 ·Status: COMPLETED ·Phase: NA
-
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
NCT00833482 ·Status: COMPLETED ·Phase: PHASE1
-
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
NCT00440947 ·Status: COMPLETED ·Phase: PHASE3